Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
Xiaosong Li, Junwei Li, Hui Li, et al.
Bioscience Reports (2020) Vol. 40, Iss. 4
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4449
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 309
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 282
Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 97
Peptides as multifunctional players in cancer therapy
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun‐Su Lee, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 6, pp. 1099-1109
Open Access | Times Cited: 87
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 30
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma
Ahmed Montasser, Aurélie Beaufrère, François Cauchy, et al.
Histopathology (2020) Vol. 79, Iss. 1, pp. 36-46
Closed Access | Times Cited: 73
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International (2022) Vol. 16, Iss. 5, pp. 1150-1160
Closed Access | Times Cited: 64
Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
Xue-Qin Gong, Ning Liu, Yun-Yun Tao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Subhamay Adhikary, Surajit Pathak, Vignesh Palani, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 217-217
Open Access | Times Cited: 10
HCC and Molecular Targeting Therapies: Back to the Future
Luca Rinaldi, Erica Vetrano, Barbara Rinaldi, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1345-1345
Open Access | Times Cited: 42
Immunotherapies in rare cancers
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Zhaoyun Liu, Xintong Xu, Hui Liu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
Xue Han, Yang-Kui Gu, Shao-long Li, et al.
Journal of Cancer Research and Clinical Oncology (2018) Vol. 145, Iss. 2, pp. 303-312
Closed Access | Times Cited: 49
Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion: A Review
Xudong Zhao, Yudan Wang, Haoming Xia, et al.
Journal of Clinical and Translational Hepatology (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Guillermo Suay, Juan Carlos García‐Cañaveras, Francisco Aparisi, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4433-4433
Open Access | Times Cited: 13
Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
Maria Pallozzi, Natalia Di Tommaso, Valeria Maccauro, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4631-4631
Open Access | Times Cited: 20
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Cancer Medicine (2025) Vol. 14, Iss. 2
Open Access
Immunoexpressions of PD-L1 and EZH2 in Endometrial Carcinoma: Associations with Clinicopathological Parameters
Badrul Iskandar Abdul Wahab, Shamsul Azhar Shah, Roslina Mohd Arshad, et al.
Diagnostics (2025) Vol. 15, Iss. 8, pp. 1042-1042
Open Access
Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
Tudor Mocan, Maria Iacobescu, Iuliana Nenu, et al.
International Immunopharmacology (2021) Vol. 94, pp. 107467-107467
Closed Access | Times Cited: 25
PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
Jin Liu, Weiling Gu, Xueqin Li, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 23
Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
Shinji Unome, Kenji Imai, Koji Takai, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6089-6089
Open Access | Times Cited: 10
Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
Mandana AmeliMojarad, Melika AmeliMojarad, Xiaonan Cui
Pathology - Research and Practice (2023) Vol. 244, pp. 154338-154338
Closed Access | Times Cited: 6
Immunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience
Roma Raj, Nihal Aykun, Chase J. Wehrle, et al.
Journal of Gastrointestinal Surgery (2023) Vol. 27, Iss. 10, pp. 2126-2134
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top